Oportuzumab monatox Terminated Phase 2 / 3 Trials for Mouth Neoplasms / Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Head And Neck Cancer / Neoplasms, Squamous Cell / Squamous Cell Carcinoma (SCC) / Head and Neck Neoplasms Treatment

Indications	Status	Purpose	Phase
DBCOND0032339 (Mouth Neoplasms) DBCOND0035874 (Squamous Cell Carcinoma of the Head and Neck (SCCHN)) DBCOND0042625 (Head And Neck Cancer) DBCOND0033322 (Neoplasms, Squamous Cell) DBCOND0043488 (Squamous Cell Carcinoma (SCC)) DBCOND0029278 (Head and Neck Neoplasms)	Terminated	Treatment	2 / 3

clinicaltrials.gov Identifier	Title	Drugs
NCT00272181	Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer	Oportuzumab monatox (DB05319)